This article has Open Peer Review reports available.
Pathology of rituximab-induced Kaposi sarcoma flare
© Pantanowitz et al; licensee BioMed Central Ltd. 2008
Received: 17 March 2008
Accepted: 23 July 2008
Published: 23 July 2008
Kaposi sarcoma (KS) flare may occur following therapy with corticosteroids, as part of the immune reconstitution inflammatory syndrome seen with highly active antiretroviral therapy (HAART), and after rituximab therapy. The exact mechanism responsible for iatrogenic KS flare is unclear.
A case of AIDS-associated cutaneous KS flare following rituximab therapy was compared to similar controls by means of immunohistochemistry using vascular makers (CD34, CD31), monoclonal antibodies to Human Herpesvirus 8 (HHV8) gene products (LNA-1, K5), as well as B-lymphocyte (CD20) and T-lymphocyte (CD3, CD4, CD8) markers.
CD20+ B-cell depletion with rituximab in KS flare occurred concomitantly with activation of the HHV8 immediate early gene protein K5. KS flare in this patient was successfully treated with liposomal doxorubicin and valganciclovir.
Rituximab-induced KS flare appears to be related to HHV8 activation. Effective management of iatrogenic KS flare therefore depends upon the control of HHV8 viremia in conjunction with specific chemotherapy for KS.
Kaposi sarcoma (KS) is a multifocal, angioproliferative tumor related to Kaposi's Sarcoma Herpesvirus/Human Herpesvirus-8 (KSHV/HHV8) infection. HHV8 is a member of the gamma-herpesvirinae sub-family, in which gene expression and viral replication are regulated by latent, immediate early, early, and late viral gene transcription . During latency, certain viral genes such as the Latency-associated nuclear antigen (LANA or ORF73) are critical for replication and maintenance of the HHV8 episome in latently infected cells. Immediate early genes (e.g. K3 and K5) code for transcriptional activators and are critical for initiating viral transcription . K5, also known as modulator of immune recognition 2 (MIR2), is a transmembrane-spanning ubiquitin-ligase that mediates the ubiquitination of cytoplasmic proteins of other transmembrane proteins, such as major histocompatibility complex-I (MHC-I) molecules. Down regulation of MHC-I molecules by K5 gene expression during reactivation is important for evading the host's immune system, because this process inhibits the presentation of viral antigen to cytotoxic T cells .
Histologically, KS lesions are comprised of spindled shaped tumor cells, abnormal vessels and a variable chronic lymphoplasmacytic inflammatory infiltrate. KS lesions grow from an early patch stage, to form plaques, which ultimately develop into a nodular (tumor) stage. Most of the cells found in both KS lesions and HHV8-infected cultures are latently infected , although both lytic and latent phases of the HHV8 life cycle play significant roles in the pathogenesis of KS. In only a small percentage of infected cells is lytic replication of HHV8 observed .
KS exacerbation (flare or recrudescence) has been documented following therapy with corticosteroids [4–6], as part of the immune reconstitution inflammatory syndrome (IRIS) seen with highly active antiretroviral therapy (HAART) in HIV-infected persons [7–9], and after treatment with rituximab [10–13]. Rituximab is a chimeric murine/human immunoglobulin G anti-CD20 monoclonal antibody that mediates cytotoxicity against CD20+ B-cells. In the setting of human immunodeficiency virus (HIV) infection, rituximab has been increasingly used to treat multicentric Castleman disease (MCD). In a recent uncontrolled phase II study involving 21 patients with MCD that were treated with rituximab, 4 of the 11 patients (36%) who had cutaneous KS experienced progression of their KS lesions . The exact mechanism(s) responsible for KS flare are unclear, and likely involve HHV8 activation and/or alteration of the host immune system.
We present, for the first time, the pathology of rituximab-induced KS flare. By means of immunohistochemistry, we set out to study the potential role of host immunity, as well as that of specific HHV8 gene products, in the pathogenesis of KS flare.
Institutional Review Board approval from Baystate Medical Center and Beth Israel Deaconess Medical Center was obtained for this study. Informed consent was obtained from the patient to perform this study and publish the findings.
Clinical case features
List of antibodies used for immunohistochemistry of Kaposi sarcoma.
Dako M765 Mouse monoclonal
Dako M0823 Mouse monoclonal
Latent HHV8 infection
Vector VP-H913 Rabbit polyclonal
Lytic HHV8 infection
Ab13.c5 Mouse monoclonal
Dako A0452 Rabbit polyclonal
Helper T-cell subset
Vector VP-C318 Mouse monoclonal
Cytotoxic T-cell subset
Vector VP-C324 Mouse monoclonal
Dako M0755 Mouse monoclonal
KS flare and/or exacerbation is a relatively newly described phenomenon related to the use of corticosteroids, HAART, and/or rituximab therapy. Although our patient received a combination of these drugs, his KS flare was temporally associated most closely with rituximab therapy. Moreover, he did not have other clinical features to support IRIS, such as a marked increase in CD4+ lymphocyte count and decreased plasma HIV-1 viral load after receiving HAART. While the initiation of HAART is most often associated with KS regression, there have certainly been accounts of KS flare following antiretroviral treatment. In one series involving nine patients with IRIS, the mean time to onset of KS flare was 5 weeks . To the best of our knowledge, no studies have yet examined the actual pathogenesis of KS flare as a manifestation of IRIS.
To date, only a limited number of publications have reported KS flare and/or rapid progression in patients treated with rituximab . One paper documented the brisk progression of classic KS in an 80-year-old man who was receiving prednisone and rituximab for severe autoimmune hemolytic anemia . KS progression in this individual only occurred two weeks after completing rituximab infusions. His lesions did not regress, even months after stopping rituximab. Other investigators observed in responders to rituximab for HIV-associated MCD an aggravation of KS, even though the HIV-1 load and CD4 cell count in these individuals were unaffected .
The mechanism for KS development due to rituximab is undefined. Some authors postulate that by specifically depleting B cells, rituximab likely affects T-cell function (by eliminating B- and T-cell interactions), thereby facilitating KS development . Other researchers found that clinical relapse of HIV-associated MCD in individuals who failed rituximab therapy was associated with increased blood HHV8 DNA levels and a worsening of KS . In our study, we identified two unique findings in KS flare following rituximab; viz. the depletion of all lesional B lymphocytes and concomitant expression of the HHV8 gene product K5.
Lymphocytes are an integral component of KS tumors. Peripheral lymphocytes, particularly B-cells, are also the major latent reservoirs of HHV8. As compared to normal skin, KS tumors typically contain a high density of CD3+ T-lymphocytes, and fewer CD20+ B-lymphocytes . In fact, the vast majority of KS infiltrating lymphocytes are of CD3+ CD8+ immunophenotype . The evolution of KS from early to advanced disease is associated with a gradual decrease in the number of total and B lymphocytes. This is supported by a study involving 68 patients with classic KS, in which investigators found a statistically significant reduction in B-lymphocyte counts in individuals with advanced-stage KS (79/microL) compared with those in earlier stages of the disease (224/microL) . Nadir B-cell counts in a similar study of HIV infected persons also documented an association with an increased risk of KS development . Higher B-cell counts in this study of HIV-infected persons appeared to actually have a protective effect against the formation of KS lesions . Therefore, it is easy to appreciate why B-cell depletion due to rituximab therapy in our case resulted in unwanted KS flare.
Exactly how B-cell depletion causes KS growth is most likely related to HHV8. Rituximab has previously been noted to cause Hepatitis B reactivation with related fulminant hepatitis . In vivo, HHV8 within KS exists in a predominantly latent state, with less than 5% of infected cells expressing discernible lytic gene products. After stimulation, HHV8 can enter the lytic cycle by a reactivation process. Increased expression of the immediate early gene product K5 in KS flare tumor cells identified in our study may indicate HHV8 activation. In general, K5 is more frequently identified within advanced KS tumors compared to early KS lesions (unpublished observation). This explains why K5 was not identified in our control specimens of plaque stage. K5 is a modulator of immune recognition (ubiquitin ligase) that helps HHV8 evade the host's immune system during lytic replication .
Our data demonstrate that B-cell depletion with rituximab in patient's at risk for KS development may activate HHV8, resulting in unwanted KS flare. Given the expanding therapeutic use of rituximab, caution is required when using this monoclonal antibody in patients at risk for developing KS. Nevertheless, in HHV8+ patients with MCD we feel that rituximab is still the treatment of choice. Finally, based upon the resolution of our patient's KS flare following appropriate therapy, effective management of iatrogenic KS flare appears to depend upon the control of HHV8 viremia in conjunction with chemotherapy for KS. Valganciclovir, when administered for 8 weeks, has been demonstrated in a randomized placebo-controlled trial to suppress HHV8 replication . Although short term use of valganciclovir in patients who test positive for HHV8 could be considered, its clinical benefit has not been proven. Further work is required to better understand the interaction between B-cells and the lymphotropic HHV8.
- Ishido S, Wang C, Lee BS, Cohen GB, Jung JU: Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000, 74: 5300-9. 10.1128/JVI.74.11.5300-5309.2000.View ArticlePubMedPubMed CentralGoogle Scholar
- Lacoste V, de la Fuente C, Kashanchi F, Pumfery A: Kaposi's sarcoma-associated herpesvirus immediate early gene activity. Front Biosci. 2004, 9: 2245-72. 10.2741/1394.View ArticlePubMedGoogle Scholar
- Douglas JL, Gustin JK, Dezube B, Pantanowitz JL, Moses AV: Kaposi's sarcoma: a model of both malignancy and chronic inflammation. Panminerva Med. 2007, 49: 119-38.PubMedGoogle Scholar
- Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM: Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989, 110: 937-40.View ArticlePubMedGoogle Scholar
- Joo M, Soon Lee S, Jin Park H, Shin HS: Iatrogenic Kaposi's sarcoma following steroid therapy for nonspecific interstitial pneumonia with HHV-8 genotyping. Pathol Res Pract. 2006, 202: 113-7. 10.1016/j.prp.2005.11.005.View ArticlePubMedGoogle Scholar
- Jinno S, Goshima C: Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS. AIDS Read. 2008, 18 (2): 102-104.Google Scholar
- Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J: Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. 2005, 23: 5224-5228. 10.1200/JCO.2005.14.597.View ArticlePubMedGoogle Scholar
- Aboulafia DM: Kaposi sarcoma flares during effective antiretroviral treatment. AIDS Read. 2005, 15: 190-1.PubMedGoogle Scholar
- Leidner RS, Aboulafia DM: Recrudescent Kaposi's sarcoma after initiation of HAART: A manifestation of immune reconstitution syndrome. AIDS Patient Care and STDs. 2005, 19: 635-44. 10.1089/apc.2005.19.635.View ArticlePubMedGoogle Scholar
- Casquero A, Barroso A, Fernández Guerrero ML, Górgolas M: Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006, 85: 185-7. 10.1007/s00277-005-0038-4.View ArticlePubMedGoogle Scholar
- Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007, 25: 3350-6. 10.1200/JCO.2007.10.6732.View ArticlePubMedGoogle Scholar
- Clifford KS, Demierre MF: Progression of classic Kaposi's sarcoma with rituximab. J Am Acad Dermatol. 2005, 53: 155-7. 10.1016/j.jaad.2004.12.048.View ArticlePubMedGoogle Scholar
- Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P: Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007, 147: 836-9.View ArticlePubMedGoogle Scholar
- Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N: Rituximab therapy for HIV-associated Castleman disease. Blood. 2003, 102: 2786-8. 10.1182/blood-2003-03-0951.View ArticlePubMedGoogle Scholar
- Neuville S, Agbalika F, Rabian C, Brière J, Molina JM: Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol. 2005, 79: 337-9. 10.1002/ajh.20418.View ArticlePubMedGoogle Scholar
- Husein MR: Immunohistological evaluation of immune cell infiltrate in cutaneous Kaposi's sarcoma. Cell Biol Int. 2008, 32: 157-62. 10.1016/j.cellbi.2007.08.021.View ArticleGoogle Scholar
- Valcuende-Cavero F, Febrer-Bosch MI, Castells-Rodellas A: Langerhans' cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma. An immunohistochemical study. Acta Derm Venereol. 1994, 74: 183-7.PubMedGoogle Scholar
- Stratigos AJ, Malanos D, Touloumi G, Antoniou A, Potouridou I, Polydorou D, Katsambas AD, Whitby D, Mueller N, Stratigos JD, Hatzakis A: Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol. 2005, 141: 1421-6. 10.1001/archderm.141.11.1421.View ArticlePubMedGoogle Scholar
- Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, Gotch F, Mandalia S, Bower M: Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer. 2004, 108: 473-4. 10.1002/ijc.11601.View ArticlePubMedGoogle Scholar
- Scheinfeld N: A review of rituximab in cutaneous medicine. Dermatol Online J. 2006, 12: 3-PubMedGoogle Scholar
- Tomescu C, Law WK, Kedes DH: Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol. 2003, 77: 9669-84. 10.1128/JVI.77.17.9669-9684.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A: Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008, 198: 23-30. 10.1086/588820.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6890/8/7/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.